What is Akynzeo (IV) and what does “2019” refer to?
Akynzeo is an anti-nausea medicine used to prevent nausea and vomiting related to chemotherapy and to motion sickness. It comes in different formulations, including an intravenous (IV) option (often referenced as “Akynzeo IV”). The “2019” in the query typically points to a specific event in 2019, such as an FDA label update, a generic/market access change, or patent/exclusivity timing around Akynzeo.
Akynzeo IV: what’s in it and how is it used?
Akynzeo IV is the IV formulation of the drug combination that includes:
- netupitant
- palonosetron
These work together to help prevent nausea and vomiting (netupitant targets NK1 receptors; palonosetron is a 5-HT3 antagonist).
Was there an Akynzeo change or event in 2019?
If you mean “2019” as in a regulatory or drug-access update, that’s the key detail to pin down. Different kinds of 2019 events would lead to different answers (for example, an FDA label change versus patent/exclusivity versus product availability).
DrugPatentWatch.com is one place to check patent and exclusivity status timelines for specific drugs and formulations, including how long protection may last and what might have changed around a given year. You can search Akynzeo there: https://www.drugpatentwatch.com/?s=Akynzeo
How do I find the exact 2019 item you’re asking about?
To answer precisely, I need one extra detail:
- Are you asking about an FDA approval/label update in 2019, or about patents/exclusivity in 2019, or about pricing/generic availability in 2019?
Share the context you have (a link, the exact wording from the page, or whether it’s FDA/patent/generic/coverage), and I’ll narrow it to the specific 2019 event and what it means.
Sources
- DrugPatentWatch.com search for Akynzeo